Amalgamated Bank Boosts Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Amalgamated Bank increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 937.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 7,577 shares of the company’s stock after buying an additional 6,847 shares during the quarter. Amalgamated Bank’s holdings in Krystal Biotech were worth $1,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in KRYS. Vanguard Group Inc. lifted its position in Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after acquiring an additional 35,632 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Krystal Biotech by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the period. Hood River Capital Management LLC boosted its position in Krystal Biotech by 8.1% in the first quarter. Hood River Capital Management LLC now owns 495,586 shares of the company’s stock valued at $88,180,000 after buying an additional 37,073 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Krystal Biotech by 23.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock worth $28,292,000 after buying an additional 43,709 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright lifted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Evercore ISI increased their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $178.41 on Friday. The firm has a 50-day simple moving average of $193.45 and a two-hundred day simple moving average of $179.60. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The company has a market cap of $5.10 billion, a P/E ratio of 95.41 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. During the same quarter in the prior year, the firm posted ($1.25) EPS. Krystal Biotech’s quarterly revenue was up 70283900.0% compared to the same quarter last year. Equities research analysts forecast that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).